AS01B adjuvant mechanisms and CD4 T cell responses

AS01B induces robust and durable CD4 T cell responses via a two-phase mechanism of transient inflammatory cytokine induction followed by sustained IFN-signaling pathway activation that drives context-dependent Th1 or Th2 polarization.

Abstract

AS01B adjuvant induces CD4 T cell responses through a two-phase mechanism involving initial transient inflammatory activation followed by sustained IFN-signaling pathway engagement. Studies demonstrate that AS01B triggers early innate responses including IL-6 and CRP peaking at 24 hours post-vaccination, followed by IFN-γ upregulation and activation of IFN-inducible genes (STAT1, IRF1, MX1, CXCL10) after the second dose. This innate activation directly correlates with enhanced CD4+ T cell outcomes, as multi-parametric modeling shows associations between CRP, IL-6, IFN-signaling pathway activation and subsequent CD4 responses. AS01B consistently induces superior CD4 T cell responses compared to AS02A (3.1-fold higher frequencies), AS03 (5.4-fold higher), AS04 (2.8-fold higher), and aluminum adjuvants, with exceptional durability extending 18-36+ months post-vaccination.

The CD4 response polarization induced by AS01B is context-dependent rather than fixed. Protein/AS01B formulations activate PPAR, FcεRI, and TGF-β pathways, inducing Th2/Tfh2-biased responses that correlate with enhanced antibody production and memory B cell frequencies. In contrast, most other AS01B formulations primarily activate IFN-signaling pathways, driving strong Th1 responses characterized by high IFN-γ production. AS01B’s superiority depends on both liposomal delivery and optimal component dosing, as AS01E containing half the MPL/QS-21 produces comparable innate profiles but 2.2-fold lower CD4 responses. The synergistic combination of MPL and QS-21 in liposomes appears critical for maximal CD4 activation.

Results

Characteristics of included studies

AS01B mechanisms at the innate immunity level

CD4 T cell responses induced by AS01B

Comparative adjuvant effects

Synthesis

The evidence reveals AS01B functions through a two-phase mechanism linking innate activation to durable CD4 responses. In the innate phase, AS01B induces transient inflammatory mediators (IL-6, CRP) peaking at 24 hours, followed by delayed IFN-signaling pathway activation after the second dose (days 31-33). This innate activation then drives robust CD4 T cell responses characterized by high magnitude, extended durability (18+ months), and context-dependent Th1/Th2 polarization.

The Th1/Th2 skewing appears platform-dependent rather than contradictory. Protein/AS01B formulations induced Th2/Tfh2-biased responses with enhanced humoral immunity, while most other contexts showed strong Th1 responses. This likely reflects differential pathway activation: PPAR, FcεRI, and TGF-β pathways were upregulated with protein/AS01B, while IFN-signaling dominated in other formulations. Both patterns ultimately enhanced vaccine immunogenicity through complementary mechanisms—Th1 for cellular immunity and Th2 for antibody production.

AS01B’s superiority over AS02A formulations (efficacy 50% vs 32%; 3.1-fold more CD4 cells) likely stems from its liposomal versus emulsion-based delivery of MPL/QS-21. The dose-response relationship is evident: AS01E with half the MPL/QS-21 induced 2.2-fold lower CD4 responses, despite comparable innate profiles. This suggests AS01B’s enhanced efficacy requires both optimal component dosing and liposomal formulation for maximal CD4 activation.

The mechanistic link between innate and adaptive responses is supported by modeling showing CRP, IL-6, and IFN-signaling pathway activation post-dose 2 predicting CD4+ T-cell outcomes. The delayed IFN-γ increase after the second injection suggests a priming-boosting mechanism where initial innate activation conditions the immune system for enhanced CD4 responses upon rechallenge. This explains AS01B’s exceptional durability—responses persisted 3+ years versus weeks for many adjuvants—likely through establishment of long-lived memory CD4+ T cells promoted by sustained IFN-γ production.

References

1. M. Fochesato, Najoua Dendouga, M. Boxus (2016). 2. G. Leroux-Roels, A. Marchant, J. Lévy et al. (2016). 3. I. Leroux-Roels et al. (2010). 4. P. Vandepapelière et al. (2008). 5. C. Nielsen et al. (2021). 6. W. Burny et al. (2017). 7. S. Pichyangkul et al. (2004). 8. K. Kester et al. (2009). 9. G. Leroux-Roels et al. (2014). 10. C. Brando et al. (2006)